Browsing Clinical Studies by author "Gore, Martin"
Now showing items 1-2 of 2
-
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii, S; Gourley, C; Kumar, R; Geuna, E; Ern Ang, J; et al. (2017-07)Background The PARP inhibitor olaparib was recently granted Food and Drug Administration (FDA) accelerated approval in patients with advanced BRCA1/2 mutation ovarian cancer. However, antitumor responses are observed in ... -
Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib.
Seifert, H; Fisher, R; Martin-Liberal, J; Edmonds, K; Hughes, P; et al. (2016-04)The BRAF inhibitor vemurafenib is an effective drug in patients with BRAF mutant metastatic melanoma, but resistance occurs after a median of 6 months. The anti-CTLA4-antibody, ipilimumab, is a standard first-line and ...